Oral mucositis drug approved for use in some Ca.(Dermatologic Therapy)
Publication: Skin & Allergy News
Publication Date: 01-FEB-05
Author: Evans, Jeff
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
The Food and Drug Administration has approved the recombinant human keratinocyte growth factor palifermin as the only drug indicated to reduce the incidence and duration of severe oral mucositis in patients with hematologic cancers who require hematopoietic stem cell transplantation after chemoradiotherapy.
Prior to palifermin, clinicians could offer only analgesics to reduce the severe pain that accompanies oral mucositis and antibiotics to reduce the risk of systemic infection.
The limited indication given so far to palifermin could widen in the future to include other indications, based on the results of upcoming studies of palifermin in...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
